Zenosense currently holds an exclusive global license agreement for the
development and marketing of revolutionary sensor devices designed to detect
the MRSA “Super-Bug” (Methicillin-resistant Staphylococcus aureus), as well as
lung cancer, in the exhaled breath of patients via a proprietary fusion of
technologies that can actually sniff out associated VOC (volatile organic
compound) biomarkers. Currently, lung cancer is the leading cancer killer and
results in some 1.6M deaths per year, or more than the next three most common
types of cancer combined, according to World Health Organization statistics.
Until recently, a widely accepted screening technology for accurately
detecting early-stage lung cancer has not been readily available (ultrasound
and X-Rays are largely ineffective at catching tumors early). The low-dose
computed tomography (LDCT) scans which have emerged are rather involved for the
patient and the healthcare facility administering them, they carry the same or
greater component risks as a typical CT scan (which can damage DNA and actually
trigger tumor growth), they lack robust specificity (high false-positive rate),
and LDCT scans typically run somewhere in the ballpark of $500 a pop. Moreover,
in lung cancer cases, as is the case with MRSA infections, early detection is
key (making cumbersome or costly testing methods untenable for many) not only
for survival rates and delimiting damage to the patient’s body, but for curbing
the systemic cost impact to the healthcare system as well.
The global market for drugs alone to treat NSCLC (non-small-cell lung
cancer), the most common type of lung cancer, accounting for around 90% of all
cases, is on track to hit $6.9B by 2019, led by companies like AstraZeneca
(NYSE: AZN), Roche (OTCM: RHHBY), and Merck (NYSE: MRK). In fact, the overall
treatment market is estimated as growing at a CAGR of roughly 4.84% over the
same interval, with yet-emerging markets like India seeing a much higher CAGR
of around 13.47% through 2015, according to a GBI Research report which was
published in September of 2014 by Transparency Market Research.
Looking at the sprawling global cancer diagnostics market, lung cancer
accounted for the largest share of the space last year and is estimated as
continuing to grow alongside cancer runaway incident rates, steadily rising for
the foreseeable future. Hence the significance to investors of a device like
the one being developed by Zenosense (OTCQB: ZENO), under an agreement with
European sensor developer Sgenia Group, via Sgenia’s Zenon Biosystem
subsidiary. Estimated manufacturing costs for the device(s) of only $100, or
possibly as little as half that sum, due to incredible advances made by
Sgenia/Zenon in the field of sensor engineering technologies, promises to bring
to market an affordable, highly-accurate system for early detection of both
deadly bacteria and certain cancers.
Utilizing established Sgenia programming and patent-pending hardware, the
devices create tens of thousands of “virtual sensors” off of a single physical
sensor, allowing for a nearly infinite number of scans to be rapidly performed.
Designed to simply be worn by patients and/or be placed in sensitive areas in
primary healthcare settings, the lung cancer detection device continuously
monitors patient headspace for exhaled breath, which is then screened for the
relevant biomarkers. An ingenious fusion of biochemistry, microbiology,
molecular biology, nanotechnology, polymer electrochemistry and sensor
engineering with high-level mathematics, the company’s devices may hold the key
to saving countless lives through early detection and, in the case of
healthcare acquired infections (HAIs) like MRSA alone, as much as $31.5B a year
in medical costs inside the U.S. (CDC data).
As of November 2014 the company had reported manufacturing of a
pre-commercial prototype lung cancer detection device and subsequently
announced in December that Zenon had entered into a collaboration agreement to
run a 400-patient trial with a university and large university hospital in
Madrid. Given the relative treatability of lung cancer when it is still in
Stage 1, the success of a non-invasive and cost-effective screening device like
this, which could be ubiquitously disseminated throughout the healthcare
system, could lead to the device becoming an industry standard, as well as huge
revenue streams for ZENO.
For more information, visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that
have huge potential to succeed in the short and long-term future. We offer
several ways for investors to find, evaluate, and learn more about investing in
these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
No comments:
Post a Comment